Navigation Links
SemBioSys to present new data at American Diabetes Association,annual meeting

TSX symbol: SBS

CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced that it will be presenting a scientific poster and abstract at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The Company's poster will disclose recent accomplishments in the development of a highly-scalable, low cost source of recombinant human insulin. Poster session presentations will take place at the McCormick Place Convention Center on Saturday June 23 from 6:00pm to 7:15 pm and on Monday June 25 from 12:00pm to 2:00pm. The poster and abstract are titled:

"Chemical and Biological Characterization of Recombinant Human Insulin Produced in Transgenic Plants." Abstract Number 0459-P by Joseph Boothe, Cory Nykiforuk, Elizabeth Murray, Philip Kuhlman, W. Brent Pollock, Amanda Bodero, Joseph Goren, Richard Keon, Nancy Markley, and Maurice Moloney.

About SemBioSys Genetics Inc. (www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead candidate is recombinant human insulin produced in the plant host safflower, to serve the rapidly expanding global diabetes market and to supply insulin for inhalation and other alternative insulin delivery technologies. The Company's other protein-based pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is also developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:, Internet: www.sembiosys.com; Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: bauma@sembiosys.com rmarshall@equicomgroup.com

Ticker Symbol: (Toronto:SBS.)

Terms and conditions of use apply
Copyr ight © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
6. Data to be presented at AAN Meeting -Study results of drug candidate for MS
7. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
8. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
9. Data supporting three Antisoma programmes presented at AACR
10. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to ... ... Volume, Company Analysis and Forecast to 2022 provides a comprehensive ... The growing prevalence of hearing impairment coupled with an expanding ...
(Date:1/20/2017)... , Jan. 20, 2017  Palladian Health, ... has announced the launch of an opioid management ... guidelines on opioids and helps stem the growing ... often prescribed to treat chronic non-cancer pain (back ... serious risks and lack of evidence regarding long-term ...
(Date:1/19/2017)... 2017 Germany Cataract Surgery ... new report, "Germany Cataract Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Phacoemulsification Equipment and Ophthalmic ... shares and distribution shares data for each of these ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on ... of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of ... 19 years of age, he joined the Navy and got married right out of boot ...
(Date:1/20/2017)... ... 20, 2017 , ... D R Burton Healthcare Products LLC, ... featured in a study indicating superior performance against competitive products in secretion clearance. ... Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter ...
(Date:1/20/2017)... ... ... enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is the ... devoted woman of faith. , “Becoming a parent changes you. In my case, the ... years, but actually doing it might have been a while in coming if it hadn’t ...
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):